 BERKELEY, Calif. and VANCOUVER, British Columbia, Feb. 23, 2021 GLOBE NEWSWIRE -- BriaCell Therapeutics Corp. TSX-V:BCT NASDAQ: BCTX, BCTXW BriaCell or the Company, a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, today announced the pricing of an underwritten public offering in the United States of 5,882,353 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock or units consisting of one pre-funded common stock purchase warrant Pre-Funded Warrant and one warrant to purchase one share of common stock, in lieu thereof. Each unit is being sold to the public at a price of US4.25 inclusive of the exercise price of the Pre-Funded Warrant, in the case of the units containing Pre-Funded Warrants. The gross proceeds to the Company from the offering are expected to be approximately US25 million before deducting underwriting discounts, commissions and other offering expenses. The warrants will have a per share exercise price of US5.3125, be exercisable immediately, and expire five years from the date of issuance. The Pre-Funded Warrants will be exercisable at any time after the date of issuance upon payment of the exercise price of 0.01 per common share. The common stock or Pre-Funded Warrant and warrants that are part of the units can only be purchased together in the offering but will be issued separately. 